Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 2/20 | 0.39 |
| ▸ | MC3R | P41968 | 2/20 | 0.39 |
| ▸ | MC1R | Q01726 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47157 | 0.86 | MC4R (0.51) | MC4RHRH3NPC1BCHECNR2 | |
| SCHEMBL47155 | 0.85 | HRH3 (0.49) | MC4RHRH3NPC1BCHECNR2 | |
| SCHEMBL47253 | 0.85 | HRH3 (0.50) | MC4RHRH3NPC1BCHECNR2 | |
| SCHEMBL47156 | 0.85 | HRH3 (0.48) | MC4RHRH3NPC1BCHECNR2 | |
| SCHEMBL47158 | 0.84 | HRH3 (0.49) | MC4RHRH3NPC1BCHECNR2 | |
| SCHEMBL15078325 | 0.82 | MC4R (0.57) | MC4RNPC1BCHECNR2MC5R | |
| SCHEMBL47113 | 0.78 | MC4R (0.52) | MC4RHRH3NPC1BCHECNR2 | |
| SCHEMBL40944 | 0.77 | MC4R (0.57) | MC4RNPC1BCHECNR2MC5R | |
| SCHEMBL41222 | 0.77 | MC4R (0.60) | MC4RNPC1BCHECNR2MC5R | |
| SCHEMBL47143 | 0.76 | MC4R (0.46) | MC4RHRH3NPC1BCHECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
| WO-2012003576-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885HRH3 88/4885NPC1 3129/4885 |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885HRH3 72/4885NPC1 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.